Coexistence of p16/CDKN2A homozygous deletions and activating EGFR mutations in lung adenocarcinoma patients signifies a poor response to EGFR-TKIs
Lung adenocarcinoma patients with epidermal growth factor receptor (EGFR)-activating mutation and genotype p16/CDKN2A homozygous deletion (n = 31) were compared with those without the deletion (n = 96) relative to their response to EGFR-TKI therapy. The deletion was associated with overall poorer response (P = .0027) and lower median PFS (5.3 months vs 10.5 months). […]
